Shire $5.9 billion acquisition of Dyax

Value:

$ 5.9 billion

Status:

Completed

Date:

22/1/2016

Dublin-based pharmaceutical company Shire has completed its $5.9 billion acquisition of Dyax.
Dyax focuses on developing treatments for rare diseases.
The deal was first announced in November 2015, less than a year after the completion of Shire's acquisition of NPS Pharmaceuticals.
Morgan Stanley, Deutsche Bank and Evercore acted as financial advisers for Shire, while Centerview Partners served as financial adviser for Dyax.

Kurt Stumpo - Journalist

United States
Ireland

Public acquisition

M&A

Pharmaceuticals and life sciences

Latham & Watkins

Party: Centerview Partners (Financial adviser)

Lawyer: Charles Ruck

Ropes & Gray

Party: Shire (Acquirer)

Lawyers: Christopher Comeau, Paul Kinsella

Slaughter and May

Party: Shire (Acquirer)

Lawyer: Azadeh Nassiri

Sullivan & Cromwell

Party: Dyax (Target)

Lawyer: Matthew Friestedt